Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Safety, Tolerability, and Efficacy of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) Who Have Completed Study 4658-102 (NCT03218995)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participant successfully completes 96 weeks of treatment in Study 4658-102.~Exclusion Criteria:~* Participant has a prior or ongoing medical condition that, in the Investigator's opinion, could adversely affect the safety of the participant, or make it unlikely that the course of treatment or follow-up would be completed, or impair the assessment of study results.~Other inclusion/exclusion criteria apply.

- Gender: MALE
- Minimum Age: 2 Years
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- Eteplirsen (Type: EXPERIMENTAL): Participants will receive eteplirsen via IV infusions, once weekly, for up to 284 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).